A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Clinical Study to Demonstrate the Safety and Effectiveness of the ShortCut™ device for splitting bioprosthetic aortic valve leaflets in patients who are presented for a valve-in-valve transcatheter aortic valve replacement (TAVR) procedure, and who are at risk for TAVR-induced coronary artery ostium obstruction.
4 Primary · 9 Secondary · Reporting Duration: 90 days post procedure
70 Total Participants · 1 Treatment Group
Primary Treatment: ShortCut™ · No Placebo Group · N/A
Age 18 - 100 · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: